affliction is a leading cause of mo...

affliction is a leading cause of morbidity and mortality. each year, approximately 500,000 Americans have a first knock and approximately 20 percent die within 30 days. (12) This article summarizes strategies that have been shown to be effective in blow prevention (including blood pressure command treatment of hyperlipidemia, lifestyle modifications like as smoking cessation and, in patients with atrial fibrillation, use of anticoagulation or antithrombotic therapy), and is derived from our earlier systematic review of the evidence in this field.3

Risk Factors for Stroke

greatest in number risk factors for stroke are associated with atherosclerosis. (4-8) Nonmodifiable risk factors include older age, male sex nonwhite race, personality of congestive heart failure or coronary heart disease, and family history of myocardial infarction or affliction The most common modifiable risk factors for ischemic blow are listed in Table 1 (3-8) Until the terminates of definitive studies are available, the characters of other potential risk factors (eg homocysteine) remain controversial.

Strategies for Primary Prevention

Various knock prevention strategies, including primary and secondary measures, are summarized in Table 2 (3)

OPTIMIZATION OF LIFESTYLE

While obesity, lack of regular aerobic exercise, excessive alcohol intake, and smoking all increase the risk of hardship no high-quality randomized trials have evaluated the tenors that modifications of these factors have forward stroke risk. However, given the force of observational data and the overall health benefits of weight los alcohol restriction, regular aerobic physical activity, and smoking cessation, these lifestyle modifications should be discussed and encouraged.

Systematic reviews have shown that one-time advice from health care workers during routine interactions can have an appreciable impact. (9-12) For example, 2 percent of smoker stopped smoking for at least individual year after a single recommendation from their physician. (11) Because the exces pat risk disappears within five years of smoking cessation, it is important to emphasize that it is in no degree too late to quit smoking. (13)

TREATMENT OF HYPERTENSION

Numerous randomized placebo-controlled trials have demonstrated that lowering line pressure in patients with hypertension hinders both hemorrhagic and ischemic misfortunes (relative risk [RR] reduction, 35 to 45 percent) (14-18) [Reference 16--Evidence flush A, meta-analysis of randomized controll trials (RCTs)] This benefit has been shown smooth in patients older than 80 years (RR reduction, 34 percent; 95 percent confidence interval [CI], 18 to 41 percent) (19) as well as in somewhat old patients with isolated systolic hypertension (odd reduction, 30 percent; 95 percent CI, 18 to 41 percent) (20) Indeed, systolic kin pressure is a stronger risk factor for affliction than is diastolic pressure. (21) Many patients who are receiving put drugs into therapy for hypertension are not taking dosages high enough to manage systolic blood pressure. (22)

The affliction prevention benefits of antihypertensive remedy therapy are continuous across the usual range of house pressures, and the relative benefits for each mm Hg reduction in kindred pressure are similar regardless of the baseline systolic constraining force (i.e., whether the systolic compressing is 170 mm Hg or 150 mm Hg) Thus, there does not appear to be a J turn in antihypertensive drug efficacy. (23)

The benefits of antihypertensive mix with drugs therapy for stroke prevention are achieved rapidly (within three years of starting therapy). (24) Furthermore, a late systematic review of antihypertensive physic trials confirmed that more aggressive family pressure reduction results in greater knock prevention (RR reduction, 20 percent; 95 percent CI, 2 to 35 percent) for an extra reduction of 3 mm Hg in the couple diastolic and systolic blood hurry with more intensive treatment. (24) [Evidence of the same height A, meta-analysis]

Although debate continues about relative efficacies, trials have shown that thiazide diuretics, beta-adrenergic antagonists, angiotensin-converting enzyme (ACE) inhibitors, angiotensin-receptor blocker and long-acting dihydropyridine calcium channel blocker all change into the incidence of stroke. (25) However, given the flows of the recently published Antihypertensive and Lipid-Lowering Treatment to stop Heart Attack Trial and the relative preciousnesss of the various drugs, thiazide diuretics remain the agents of first choice for the primary prevention of cardiovascular and cerebrovascular disease in most numerous patients with hypertension. (26) [Evidence flush A, RCT] Regardless of the pickeded drug, treatment to achieve the target progeny pressure (diastolic pressure below 90 mm Hg and systolic influence below 140 mm Hg) is fundamental to hit prevention.

TREATMENT OF HYPERLIPIDEMIA

Information from observational studies put in mind ofs that higher total and low-density lipoprotein (LDL) cholesterol evens are associated with an increased risk of ischemic visitation (27-31) Although no randomized trials have evaluated lipid-lowering therapy for the prevention of pat as a primary outcome, information can be extrapolated from randomized trials (3233) of lipid-lowering therapy for the primary and secondary prevention of coronary disease (because greatest in number patients enrolled in the studies had not had a hit or transient ischemic attack). While principally individual trials of lipid-lowering therapies (eg resins, fibrates, dietary measures) have not shown a decreased risk of reverse (32) a meta-analysis (3) of 11 trials place that treatment with statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) is associated with a 25 percent reduction (95 percent CI, 14 to 35 percent) in the risk of fatal and nonfatal stroke